Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

The interplay between sex and serious bacterial infections, including bacteremia and sepsis, is complex and more research is ...

Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...

The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...

The World Health Organization (WHO) has released an update on polio following the March 2025 meeting of the International ...

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF ...